MARKET

RCKT

RCKT

Rocket Pharmaceu
NASDAQ
17.22
+1.72
+11.10%
After Hours: 17.40 +0.18 +1.05% 17:03 10/04 EDT
OPEN
16.45
PREV CLOSE
15.50
HIGH
17.67
LOW
16.45
VOLUME
3.79M
TURNOVER
0
52 WEEK HIGH
36.87
52 WEEK LOW
7.57
MARKET CAP
1.14B
P/E (TTM)
-5.8001
1D
5D
1M
3M
1Y
5Y
Update: Rocket Pharmaceuticals Prices $100.3 Million Common Stock Offering; Shares Climb Tuesday
Update: Rocket Pharmaceuticals Prices $100.3 Million Common Stock Offering; Shares Climb Tuesday
MT Newswires · 14h ago
Rocket Pharmaceuticals Priced 6.*M Share Public Offering of Common Stock @ $14.75/Share
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a public offering price of $14.75 per share.
Benzinga · 20h ago
Rocket Pharmaceuticals shares slide on pricing $100.3M stock offering
Rocket Pharmaceuticals (NASDAQ:RCKT) shares <font color="re...
Seekingalpha · 21h ago
Rocket Pharmaceuticals Prices $100.3 Million Common Stock Offering
Rocket Pharmaceuticals Prices $100.3 Million Common Stock Offering
MT Newswires · 1d ago
BRIEF-Rocket Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
BRIEF-Rocket Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Reuters · 1d ago
Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Rocket Pharmaceuticals (NASDAQ:RCKT) stock <font color="red...
Seekingalpha · 1d ago
BRIEF-Rocket Pharmaceuticals Announces Proposed Public Offering Of Common Stock
BRIEF-Rocket Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Reuters · 1d ago
Rocket Pharmaceuticals Announces Proposed Public Offering Of $100M Of Shares Of Its Common Stock
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high
Benzinga · 1d ago
More
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Danon Disease, Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO). FA is a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells. LAD-I is a genetic disorder that causes the immune system to malfunction. PKD is a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. IMO is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Webull offers kinds of Rocket Pharmaceuticals Inc stock information, including NASDAQ:RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.